EuropaBio statement on court ruling that impacts genome-edited products

Written by EuropaBio on 20 December 2018 in Press Release
Press Release

EuropaBio calls for change, following court ruling that impacts genome-edited products.

The European biotechnology industry warns that the recent EU court ruling impacting many products made with genome editing could cause European life science innovation to effectively come to a halt.

This would hinder EU sustainability and competitiveness ambitions, from the delivery of innovative bio-based products to sustainable food and certain healthcare solutions.

EuropaBio calls for science-based, predictable and proportionate rules, instead of disproportionate regulatory requirements, when the very same products could also be obtained through earlier breeding or classical mutagenesis methods or could simply result from spontaneous processes in nature.

Access the full statement here.

Share this page

Tags

Categories

Partner content

This content is published by the Parliament Magazine on behalf of our partners.

Related Partner Content

Europe must continue to invest in the bioplastic revolution
23 October 2018

It is imperative to seize the momentum of recent policy developments at both European and international level, argues Philippe Mengal.

How Europe has priced out innovation: the example of plants
16 January 2019

Europe is lagging behind on several breakthrough technologies, especially in the field of agricultural biotechnology, explains Joanna Dupont-Inglis.

PM+: GMO authorisation needs legal certainty
26 October 2015

Ahead of the European Parliament’s vote on the use of GMOs, Nathalie Moll calls for a shift to a more coherent and science-based approach to EU policymaking.